drugset / Trial / NCT02963779

A Study of LY2775240 in Healthy Participants

NCT02963779

Phase 1 Completed 35 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

This study is conducted to determine the side effects related to LY2775240 given orally to healthy participants. Blood tests will be done to check how much LY2775240 is absorbed into the bloodstream and how long the body takes to get rid of it. Each participant will enroll in either Part A or Part B of the study, which will last about 14 weeks and 8 weeks respectively, including screening.

Timeline

Start
2016-12
Primary completion
2017-10-05
Completion
2017-10-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apremilast Small molecule Oral
Subject LY2775240 Unknown Oral

Indications

No indication recorded.